All In Biotech

Drug Trial Radar · NCT00540787

A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation

A Randomized Comparison of the Efficacy of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation for the Maintenance of Sinus Rhythm In Patients With Paroxysmal Atrial Fibrillation

Last checked: Nov 20, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 112 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

112

Actual

Start

Aug 1, 2003

Primary completion

Jun 1, 2006

Study completion Jun 1, 2006

Sponsor

Lead sponsor
Biosense Webster, Inc.Industry
Sponsor type
Industry
First posted
Oct 8, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare radiofrequency catheter ablation and antiarrhythmic drug treatment for the maintenance of sinus rhythm in paroxysmal atrial fibrillation patients.

Conditions

  • Paroxysmal Atrial Fibrillation

Interventions

  • Radiofrequency ablation, antiarrhythmic drugsDevice

    Patients receive either treatment.

  • Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugsDrug

    Amiodarone will be taken at 600 mg per day for 21 days (as a loading dose) followed by 1.4g per week or 200mg per day. The daily dose may be increased to 300mg or 2.1g per week.

  • ThermoCool Radiofrequency CatheterDevice

    Patient is ablated once, repeat ablation if paroxysmal atrial fibrillation reoccurs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence of Atrial FibrillationTime frame: One year

Locations

6 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama, Birmingham

    Birmingham, Alabama

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Mid-Ohio Cardiology

    Columbus, Ohio

  • Hopital Lariboisiere

    Paris, France

  • Hôpital Haut Lèvêque

    Pessac, Paris, France

  • Hopital Cantonal de Geneve

    Geneva, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.